Clinical Feasibility of Disease Managing Mobile App for Hyperthyroidism
Study Details
Study Description
Brief Summary
This randomized controlled study aims to investigate the effects of using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. The study intends to evaluate how the use of the app affects disease progression, quality of life, and health-related behaviors associated with the disease.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: app user group The participants in this group start using wearable devices to monitor their heart rate and a mobile app to assist with the management of hyperthyroidism after being diagnosed and beginning treatment with anti-thyroid medication. |
Other: Using a mobile app that integrates with wearable devices
Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
|
No Intervention: non-user group The participants in this group begin treatment with anti-thyroid medication after being diagnosed with thyrotoxicosis, but they do not use the wearable devices or mobile app used in this study. |
Outcome Measures
Primary Outcome Measures
- Scores of quality of life assessed by SF-36 survey [baseline (at enrollment)]
Scores of quality of life assessed by SF-36 survey
- Scores of quality of life assessed by SF-36 survey [6 weeks after baseline]
Scores of quality of life assessed by SF-36 survey
- Scores of quality of life assessed by SF-36 survey [10 weeks after baseline]
Scores of quality of life assessed by SF-36 survey
- Scores of quality of life assessed by SF-36 survey [14 weeks after baseline]
Scores of quality of life assessed by SF-36 survey
- antithyroidal drug compliance [6 weeks after baseline]
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
- antithyroidal drug compliance [10 weeks after baseline]
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
- antithyroidal drug compliance [14 weeks after baseline]
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
- Knowledge about hyperthyroidism [14 weeks after baseline]
A score measured through a test designed to assess the knowledge level about Graves' disease
Secondary Outcome Measures
- free T4 [baseline]
serum free T4 concentration
- free T4 [6 weeks after baseline]
serum free T4 concentration
- free T4 [10 weeks after baseline]
serum free T4 concentration
- free T4 [14 weeks after baseline]
serum free T4 concentration
- free T3 [baseline]
serum free T3 concentration
- free T3 [6 weeks after baseline]
serum free T3 concentration
- free T3 [10 weeks after baseline]
serum free T3 concentration
- free T3 [14 weeks after baseline]
serum free T3 concentration
- TSH [baseline]
serum free TSH concentration
- TSH [6 weeks after baseline]
serum free TSH concentration
- TSH [10 weeks after baseline]
serum free TSH concentration
- TSH [14 weeks after baseline]
serum free TSH concentration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects who have been newly diagnosed or are currently undergoing treatment for thyrotoxicosis at Bundang Seoul National University Hospital.
-
Subjects must be able to use the smartphone app required for the use of wearable devices and their integration.
Exclusion Criteria:
-
Subjects who have constraints on normal activity due to diseases other than thyroid dysfunction.
-
Subjects who are currently taking medication that affects heart rate.
-
Subjects with heart conditions such as arrhythmia that affect heart rate.
-
Subjects who cannot undergo antithyroid drug treatment and require surgery or radioactive iodine therapy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Seoul National University Bundang Hospital | Seongnam-si | Gyeonggi-do | Korea, Republic of | 13620 |
Sponsors and Collaborators
- Seoul National University Bundang Hospital
- Thyroscope Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B-2201-735-304